Post-stroke cognitive impairment (PSCI) is a kind of common complications after stroke, which seriously affects the functional recovery. The diagnosis of PSCI mainly depends on imaging measures and scale assessments at present, but these methods have some limitations. Blood samples are relatively convenient to collect for biomarker detection, and uitable for practical application in a clinical setting. Along with a remarkable development of molecular biology, increasing studies have shown that biomarkers of neuroinjury, inflammation and oxidative stress have played important roles in the development and progression of PSCI. Herein we review the progress and pathogenesis of blood biomarkers for PSCI, and the application of these biomarkers in prevention and early diagnosis of PSCI.

【Objective】 To analyze the distribution of unexpected antibodies in tumor patients retrospectively and explore the clinical significance. 【Methods】 Unexpected antibody screening was performed on inpatients with blood preparation and blood transfusion in our hospital from January 2004 to December 2022, with 1 176 cases tested positive, and the types of unexpected antibodies and distribution characteristics were statistically analyzed. 【Results】 Unexpected antibodies were screened in 1 176 cases, with the positive rate at 1.05% (1 176/111 483). The unexpected antibodies were mainly anti-E 16.33%(192/1 176), anti-M 7.99% (94/1 176), anti-Mur 5.70% (67/1 176) and anti-Le^a 4.76% (56/1 176). Among the 1 176 cases, gastrointestinal tumors accounted for 27.99% (329/1 176), gynecological tumors accounted for 24.84% (292/1 176), respiratory tumors accounted for 16.67% (196/1 176) . 【Conclusion】 The influencing factors of unexpected antibodies in tumor patients were disease type, blood transfusion history and blood type. Therefore, it is necessary for clinical departments to carry out unexpected antibody screening and perform Rh blood type matched transfusion for tumor patients to avoid alloantibody production.